Reply to: "HCC prediction post SVR: many tools yet limited generalizability!": De novo HCC risk stratification after HCV cure: All roads lead to Rome?

Abstract

We would like to thank Dr. Bhagat and colleagues1 for their interest in our study on de novo hepatocellular carcinoma (HCC) risk stratification in compensated advanced chronic liver disease (cACLD) patients who achieved sustained virologic response (SVR).2 The authors provided a summary of 11 selected risk stratification approaches and highlighted 5 points related to our study but also HCC risk stratification/screening in general.